FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295547> ?p ?o ?g. }

• W4286295547 endingPage "4104" @default.
• W4286295547 startingPage "4104" @default.
• W4286295547 abstract "4104 Background: Apatinib, a tyrosine kinase inhibitor, has shown promising effects on advanced hepatocellular carcinoma (HCC) recently. However, studies on its efficacy and safety are limited with controversial findings. Therefore, this study aimed to reveal the efficacy and safety of low-dose apatinib for the treatment of advanced HCC in the real world. Methods: Between January 2017 and August 2020, 178 patients with advanced HCC treated with apatinib at three different institutions were included for the present study. 174 patients received oral apatinib 250 mg daily and 4 received 500 mg daily until disease progression. 25 and 103 patients were also treated with immunotherapy and transcatheter arterial chemoembolization (TACE) at least once, respectively. Tumor response and adverse reactions were evaluated according to RECIST 1.1 and CTCAE 5.0 respectively. Survival curves were analyzed using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic value of variables in a univariate and multivariate setting. Results: During the 24-month follow-up period, 0 (0%), 28 (15.73%), 103 (57.87%) and 47 (26.40%) patients achieved a compete response (CR), partial response (PR), stable disease (SD), and progressive disease (PR), respectively. The overall response rate (ORR) and disease control rate (DCR) were 15.73% and 73.60% respectively. Interestingly, among the 28 patients with PR, 27 received apatinib as the first or second line treatment and 21 received immunotherapy or TACE as a combined treatment, indicating early application of apatinib and combination treatment could provide better efficacy. Kaplan-Meier analysis revealed the median overall survival (OS) and progressive-free survival (PFS) were 16.0 and 7.0 months respectively, which are significantly higher than previously reported survival of sorafenib in advanced HCC. Univariate Cox analysis indicated medication lines, distant metastasis, aplpha fetoprotein (AFP) level, portal vein tumor thrombus (PVTT) and combination therapy significantly affected OS and PFS. Multivariate Cox analysis confirmed third-line treatment (HR = 3.21; 95%CI = 1.54–6.68; p= 0.002), and PVTT (HR = 1.75; 95%CI = 1.13–2.70; p= 0.011) were independently associated with worse PFS. In contrast, apatinib combined with immunotherapy (HR = 0.52; 95%CI = 0.32–0.83; p= 0.008) or TACE (HR = 0.27; 95%CI = 0.18–0.40; p< 0.001) were independently associated with better PFS. Similar findings were also present on OS. The most common treatment-related adverse events were hypertension (29.21%), fatigue (16.85%), hand and foot syndrome (16.29%), vomiting (14.04%), liver dysfunction (6.18%), and proteinuria (6.74%). No severe (grade ≥3) adverse events were observed. Conclusions: Low-dose apatinib is able to provide effective and safe treatment for advanced HCC. Early application of apatinib and combination treatment could provide even better efficacy." @default.
• W4286295547 created "2022-07-21" @default.
• W4286295547 creator A5004561803 @default.
• W4286295547 creator A5023399359 @default.
• W4286295547 creator A5026044244 @default.
• W4286295547 creator A5059317312 @default.
• W4286295547 creator A5089218949 @default.
• W4286295547 creator A5091374629 @default.
• W4286295547 date "2022-06-01" @default.
• W4286295547 modified "2023-09-27" @default.
• W4286295547 title "Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma." @default.
• W4286295547 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4104" @default.
• W4286295547 hasPublicationYear "2022" @default.
• W4286295547 type Work @default.
• W4286295547 citedByCount "0" @default.
• W4286295547 crossrefType "journal-article" @default.
• W4286295547 hasAuthorship W4286295547A5004561803 @default.
• W4286295547 hasAuthorship W4286295547A5023399359 @default.
• W4286295547 hasAuthorship W4286295547A5026044244 @default.
• W4286295547 hasAuthorship W4286295547A5059317312 @default.
• W4286295547 hasAuthorship W4286295547A5089218949 @default.
• W4286295547 hasAuthorship W4286295547A5091374629 @default.
• W4286295547 hasConcept C121608353 @default.
• W4286295547 hasConcept C126322002 @default.
• W4286295547 hasConcept C143998085 @default.
• W4286295547 hasConcept C197934379 @default.
• W4286295547 hasConcept C2777701055 @default.
• W4286295547 hasConcept C2778019345 @default.
• W4286295547 hasConcept C2778695046 @default.
• W4286295547 hasConcept C2778820342 @default.
• W4286295547 hasConcept C2778822529 @default.
• W4286295547 hasConcept C2779134260 @default.
• W4286295547 hasConcept C2779984678 @default.
• W4286295547 hasConcept C2780668389 @default.
• W4286295547 hasConcept C3019894029 @default.
• W4286295547 hasConcept C50382708 @default.
• W4286295547 hasConcept C71924100 @default.
• W4286295547 hasConcept C90924648 @default.
• W4286295547 hasConceptScore W4286295547C121608353 @default.
• W4286295547 hasConceptScore W4286295547C126322002 @default.
• W4286295547 hasConceptScore W4286295547C143998085 @default.
• W4286295547 hasConceptScore W4286295547C197934379 @default.
• W4286295547 hasConceptScore W4286295547C2777701055 @default.
• W4286295547 hasConceptScore W4286295547C2778019345 @default.
• W4286295547 hasConceptScore W4286295547C2778695046 @default.
• W4286295547 hasConceptScore W4286295547C2778820342 @default.
• W4286295547 hasConceptScore W4286295547C2778822529 @default.
• W4286295547 hasConceptScore W4286295547C2779134260 @default.
• W4286295547 hasConceptScore W4286295547C2779984678 @default.
• W4286295547 hasConceptScore W4286295547C2780668389 @default.
• W4286295547 hasConceptScore W4286295547C3019894029 @default.
• W4286295547 hasConceptScore W4286295547C50382708 @default.
• W4286295547 hasConceptScore W4286295547C71924100 @default.
• W4286295547 hasConceptScore W4286295547C90924648 @default.
• W4286295547 hasIssue "16_suppl" @default.
• W4286295547 hasLocation W42862955471 @default.
• W4286295547 hasOpenAccess W4286295547 @default.
• W4286295547 hasPrimaryLocation W42862955471 @default.
• W4286295547 hasRelatedWork W2338429711 @default.
• W4286295547 hasRelatedWork W2903742179 @default.
• W4286295547 hasRelatedWork W2970843077 @default.
• W4286295547 hasRelatedWork W3031596504 @default.
• W4286295547 hasRelatedWork W3134421065 @default.
• W4286295547 hasRelatedWork W4206788213 @default.
• W4286295547 hasRelatedWork W4210315076 @default.
• W4286295547 hasRelatedWork W4361968275 @default.
• W4286295547 hasRelatedWork W4362395425 @default.
• W4286295547 hasRelatedWork W65717035 @default.
• W4286295547 hasVolume "40" @default.
• W4286295547 isParatext "false" @default.
• W4286295547 isRetracted "false" @default.
• W4286295547 workType "article" @default.